Shanghai Haohai Biological Technology CoFRA:5HB +1.16%66 Return-on-Tangible-Equity is 6.46% as of Mar. 2026, which is 31% below its 10-year median of 9.31. GuruFocus rates FRA:5HB with a GF Score™ of 66/100 and a GF Value™ of €2.63 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Shanghai Haohai Biological Technology Co ranks better than 79.65% on this metric.
FRA:5HB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.48 Med: 9.31 Max: 16.4
Current: 2.48
During the past 12 years, Shanghai Haohai Biological Technology Co's highest Return-on-Tangible-Equity was 16.40%. The lowest was 2.48%. And the median was 9.31%.
FRA:5HB's Return-on-Tangible-Equity is ranked better than 79.65% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs FRA:5HB: 2.48
Shanghai Haohai Biological Technology Co (FRA:5HB) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai Haohai Biological Technology Co Return-on-Tangible-Equity Related Terms
Shanghai Haohai Biological Technology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co Return-on-Tangible-Equity Chart
Shanghai Haohai Biological Technology Co Annual Data
FRA:5HB vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.46% mean?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Return-on-Tangible-Equity of 6.46% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 31% below median its historical median of 9.31. Over the past decade, Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity has ranged from 2.48 to 16.40. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #244 out of 1199 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity too high?
Shanghai Haohai Biological Technology Co's current Return-on-Tangible-Equity of 6.46% is 31% below median its 10-year median of 9.31. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 16.40. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #244 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #244 out of 1199 companies for Return-on-Tangible-Equity. This places Shanghai Haohai Biological Technology Co in the top 20% of its industry — outperforming the majority of peers. Historically, Shanghai Haohai Biological Technology Co's own Return-on-Tangible-Equity has ranged from 2.48 to 16.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Return-on-Tangible-Equity is 6.46%, which is 31% below median its own 10-year median of 9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.63, compared to a current price of €1.75 — trading 33.5% below its estimated fair value. The current Return-on-Tangible-Equity is 6.46%, which is 31% below median its 10-year median of 9.31. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Return-on-Tangible-Equity is 6.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.75 is trading 33.5% below its estimated GF Value™ of €2.63.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
Return-on-Tangible-Equity: 6.46% (31% below median its 10-year median of 9.31)
GF Value™: €2.63 vs. price of €1.75 (33.5% below fair value)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
